ATE520672T1 - Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine - Google Patents

Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine

Info

Publication number
ATE520672T1
ATE520672T1 AT05803358T AT05803358T ATE520672T1 AT E520672 T1 ATE520672 T1 AT E520672T1 AT 05803358 T AT05803358 T AT 05803358T AT 05803358 T AT05803358 T AT 05803358T AT E520672 T1 ATE520672 T1 AT E520672T1
Authority
AT
Austria
Prior art keywords
carbo
hiv
inhibiting
substituted pyrimidines
heterocyclic substituted
Prior art date
Application number
AT05803358T
Other languages
English (en)
Inventor
Jerome Guillemont
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE520672T1 publication Critical patent/ATE520672T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05803358T 2004-09-30 2005-09-29 Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine ATE520672T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104814 2004-09-30
PCT/EP2005/054931 WO2006035068A2 (en) 2004-09-30 2005-09-29 Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines

Publications (1)

Publication Number Publication Date
ATE520672T1 true ATE520672T1 (de) 2011-09-15

Family

ID=34929640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05803358T ATE520672T1 (de) 2004-09-30 2005-09-29 Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine

Country Status (17)

Country Link
US (1) US7531548B2 (de)
EP (1) EP1797048B1 (de)
JP (1) JP5162245B2 (de)
KR (1) KR20070057798A (de)
CN (1) CN101031550B (de)
AR (1) AR050970A1 (de)
AT (1) ATE520672T1 (de)
AU (1) AU2005288865B2 (de)
BR (1) BRPI0515935B8 (de)
CA (1) CA2573976C (de)
ES (1) ES2371924T3 (de)
IL (1) IL180760A (de)
MX (1) MX2007003798A (de)
RU (1) RU2403244C2 (de)
TW (1) TW200626560A (de)
WO (1) WO2006035068A2 (de)
ZA (1) ZA200702655B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130602T1 (en) 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
BRPI0516746A (pt) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
RU2410379C2 (ru) * 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2465666T3 (es) * 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
WO2007113256A1 (en) * 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
CA2674178C (en) * 2006-12-29 2015-11-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines
ES2618057T3 (es) * 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
WO2008118823A2 (en) * 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ, インコーポレイテッド Btk阻害剤のベシル酸塩
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ, インコーポレイテッド 変異体選択的egfr阻害剤およびその使用
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
AU2021224460A1 (en) 2020-02-19 2022-12-15 Pharmasyntez, Joint Stock Company Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of HIV infection
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
KR20230155351A (ko) * 2022-05-03 2023-11-10 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2024103400A1 (zh) * 2022-11-18 2024-05-23 水木未来(北京)科技有限公司 作为gpr75激活剂的多环化合物、包含其的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945447A1 (de) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
HU230522B1 (hu) * 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
HU227453B1 (en) * 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
WO2002068415A1 (en) * 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos

Also Published As

Publication number Publication date
EP1797048B1 (de) 2011-08-17
AU2005288865A1 (en) 2006-04-06
MX2007003798A (es) 2007-04-23
BRPI0515935B8 (pt) 2021-05-25
JP5162245B2 (ja) 2013-03-13
IL180760A (en) 2013-02-28
IL180760A0 (en) 2007-06-03
CA2573976C (en) 2014-04-29
RU2403244C2 (ru) 2010-11-10
JP2008514680A (ja) 2008-05-08
CN101031550B (zh) 2015-05-27
WO2006035068A3 (en) 2006-08-31
ZA200702655B (en) 2008-09-25
RU2007116161A (ru) 2008-11-10
WO2006035068A2 (en) 2006-04-06
AU2005288865B2 (en) 2012-07-19
BRPI0515935B1 (pt) 2019-11-19
AR050970A1 (es) 2006-12-06
ES2371924T3 (es) 2012-01-11
TW200626560A (en) 2006-08-01
CA2573976A1 (en) 2006-04-06
CN101031550A (zh) 2007-09-05
US20070208022A1 (en) 2007-09-06
KR20070057798A (ko) 2007-06-07
US7531548B2 (en) 2009-05-12
BRPI0515935A (pt) 2008-08-12
EP1797048A2 (de) 2007-06-20

Similar Documents

Publication Publication Date Title
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
EP1724267A4 (de) Pyrimidinderivat
ATE529412T1 (de) Herbizide pyrimidine
MA28824B1 (fr) Derives de pyrimidine
MA28813B1 (fr) Derives de pyrimidine
NL2000323A1 (nl) Pyrimidine-derivaten.
EP1546115A4 (de) Substituierte pyrimidine
EP1890703A4 (de) Pyrimidinverbindungen
NO20044374L (no) Pyrimidinderivater
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
ATE437875T1 (de) Heterozyklische antivirale verbindungen
GB0525080D0 (en) Pyrimidine derivatives
ATE413389T1 (de) Chinazolinderivate
GB0525083D0 (en) Pyrimidine derivatives
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
GB0415367D0 (en) Pyrimidine derivatives
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
ATE542802T1 (de) Hiv-inhibierende 5-substituierte pyrimidine
ATE420646T1 (de) Aminopyrimidine als kinase-modulatoren
GB0525081D0 (en) Pyrimidine derivatives
ATE350370T1 (de) 2-substituierte pyrimidine
ATE366242T1 (de) 5-substituierte chinazolinonderivate
ATE417842T1 (de) Verwendung von trisubstituierten benzopyranonen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties